<DOC>
	<DOCNO>NCT00622648</DOCNO>
	<brief_summary>The primary objective : - To demonstrate patient hospitalize acute medical illness enoxaparin Graduated Elastic Stockings superior enoxaparin-placebo Graduated Elastic Stockings overall mortality day 30 randomization . The secondary objective : - To compare , patient hospitalize acute medical illness , enoxaparin Graduated Elastic Stockings versus enoxaparin placebo Graduated Elastic Stockings overall mortality day 90 randomization . - To evaluate safety enoxaparin VTE prophylaxis patient hospitalize acute medical illness respect major hemorrhage , total bleeding , heparin induce thrombocytopenia , adverse event serious adverse event .</brief_summary>
	<brief_title>Study Evaluate Mortality Reduction Enoxaparin Hospitalized Acutely Ill Medical Receiving Enoxaparin</brief_title>
	<detailed_description />
	<criteria>List inclusion exclusion criterion Hospitalization within 48 hour prior randomization least one follow medical acute medical illness : Acute decompensation heart failure Severe systemic infection least one following : Chronic pulmonary disease ( COPD , pulmonary fibrosis , pulmonary restrictive syndrome… ) Obesity ( BMI ≥ 30kg/m2 ) Personal history VTE Age ≥ 60 year Active cancer ( define histologically confirm initial diagnosis recurrence metastasis within past 6 month ) exclude plan hospitalization chemotherapy Anticipated duration hospitalization least 6 day Health status : ASA Health status score ≤ 3 ( American Society Anesthesiologists ) ECOG ≤ 2 cancer patient Anticipated life expectancy &gt; 1 week Exclusion criterion : Major surgery major trauma within previous 6 week ( orthopedic trauma surgery low extremity , gastrointestinal tract , urological , chest , gynecological surgery ) Need ventilatory support ( intubation require ) Symptomatic VTE enrollment Multi organ failure Evidence active bleeding disorder Contraindication anticoagulation : Coagulopathy ( acquire inherit ) Neurosurgery within past day 30 History cerebral hemorrhage time Known bacterial endocarditis Uncontrolled arterial hypertension ( systolic BP &gt; 200 mmHg diastolic BP &gt; 110 mm Hg ) 2 successive reading Haemostatic abnormality : baseline platelet count &lt; 50,000/mm3 , activate partial thromboplastin time ( aPTT ) 1.5x upper limit normal , International Normalized Ratio ( INR ) &gt; 1.5 Indication thrombolytic therapy Need curative treatment anticoagulant therapy ( low molecular weight heparin , unfractionated heparin , oral anticoagulant therapy ) Receiving LMWH UFH prophylactic dos 72 hour prior inclusion ( patient receive LMWH UFH prophylactic dos 72 hour less prior entry may include study ) Oral anticoagulant therapy within 72 hour prior inclusion Cerebrovascular accident inclusion within 10 day prior study inclusion Prosthetic heart valve Confirmed cerebral metastasis Known hypersensitivity heparin LMWH , porkderived product History document episode heparin , LMWH induce thrombocytopenia , and/or thrombosis ( HIT , HAT , HITTS ) Participating another clinical trial within previous 30 day ( patient cancer include cancer treatment protocol authorize participate ) Persistent renal failure ( define document value calculate creatinine clearance &lt; 30 mL/min least 2 occasion ³3 day prior entry study ) Known suspect severe anemia unexplained cause consider clinically relevant investigator Spinal epidural analgesia lumbar puncture within precede 24 hour Unlikely compliant ( e.g . alcohol , drug abuse ) Women childbearing potential protected effective contraceptive method birth control and/or unwilling tested pregnancy ( pregnancy status check serum urine pregnancy test prior exposure investigational product ) Refusal inability give inform consent participate study Inability followedup discharge day 90 randomization The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Medical prevention therapy</keyword>
</DOC>